ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases
July 28, 2021Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, today announced the closing of a $63 million Series B financing. -
Low awareness of rare diseases increases morbidity and potential mortality
June 02, 2021Orphan or rare diseases are conditions that affect a small percentage of the population in a given country. The widely accepted definition in the US is a disease that affects fewer than 200,000 people nationwide. -
Minoryx Therapeutics completes phase 1 clinical trial for MIN-102
March 23, 2017MIN-102 was well-tolerated at much higher doses than those required for efficacy
Pharma Sources Insight January 2025
